Oxidative stress and inflammation in pregnancy

Scandinavian Journal of Clinical and Laboratory Investigation

Volumn 66, Issue 2, 2006, Pages 121-128

  Fialova L ^a,c   Malbohan, I ^a   Kalousova M ^a   Soukupova J ^a   Krofta, L ^b   Stipek S ^a   Zima, T ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b INSTITUTE FOR THE CARE OF MOTHER AND CHILD   (Czech Republic)

^c CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Advanced oxidation protein products; Anticardiolipin antibodies; C reactive protein

Indexed keywords

ADVANCED OXIDATION PROTEIN PRODUCT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CARDIOLIPIN ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; PROTEIN DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; ANTIBODY BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; INFLAMMATION; MATERNAL SERUM; OXIDATIVE STRESS; PREGNANCY; PRENATAL SCREENING; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SECOND TRIMESTER PREGNANCY; STATISTICAL SIGNIFICANCE;

ADULT; ANTIBODIES, ANTICARDIOLIPIN; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INFLAMMATION; MALE; OXIDATIVE STRESS; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY TRIMESTER, FIRST; PREGNANCY TRIMESTER, SECOND;

EID: 33645013330     PISSN: 00365513     EISSN: 15027686     Source Type: Journal    
DOI: 10.1080/00365510500375230     Document Type: Article

References (26)

1. Gitto E, Reiter RJ, Karbownik M, Tan D, Gitto P, Barberi S, et al. Causes of oxidative stress in the pre- and perinatal period. Biol Neonate 2002;81:146-57.
2. Burton GJ, Jaunaiux E. Maternal vascularisation of the human placenta: does the embryo develop in a hypoxic environment? Gynecol Obstet Fertil 2001;29:503-8.
3. Arikan S, Konukoglu D, Arican C, Akcay T, Davas T. Lipid peroxidation and antioxidant status in maternal and cord blood. Gynecol Obstet Invest 2001;51:145-9.
4. Barden A, Beilin LJ, Ritchie J, Croft KD, Walters BN, Michael CA. Plasma and urinary 8-iso-prostane as an indicator of lipid peroxidation in preeclampsia and normal pregnancy. Clin Sci 1996;91:711-18.
5. Karowicz-Bilinska A, Suzin J, Sieroszewski P. Evaluation of oxidative stress indices during treatment in pregnant women with intrauterine growth retardation. Med Sci Monit 2002;8:211-16.
6. Yoneyama Y, Sawa R, Suzuki S, Doi D, Yoneyama K, Otsubo Y, et al. Relationship between plasma malondialdehyde levels and adenosine deaminase activities in preeclampsia. Clin Chim Acta 2002;322:169-73.
7. Witko-Sarsat V, Friedlander M, Capeillere-Blandin C, Nguyen-Khoa T, Nguyen AT, Zingraff J, et al. Advanced oxidation protein products as a novel marker of oxidative stress in uraemia. Kidney Int 1996;49:1304-13.
8. Witko-Sarsat V, Descamps-Latscha B. Advanced oxidation protein products: Novel uraemic toxins and proinflammatory mediators in chronic renal failure? Nephrol Dial Transplant 1997;12:1310-12.
9. Buonocore G, Perrone S, Longini M, Terzuoli L, Bracci R. Total hydroperoxide and advanced oxidation protein products in preterm hypoxic babies. Pediatr Res 2000;47:221-4.
10. Buonocore G, Perrone S, Longini M, Vezzosi P, Marzocchi B, Paffetti P, et al. Oxidative stress in preterm neonates at birth and on the seventh day of life. Pediatr Res 2002;52:46-9.
11. Kaneda H, Taguchi J, Ogasawara K, Aizawa T, Ohno M. Increased level of advanced oxidation protein products in patients with coronary artery disease. Atherosclerosis 2002;162:221-5.
12. Kalousová M, Škrha J, Zima T. Advanced glycation end-products and advanced oxidation protein products in patients with diabetes mellitus. Physiol Res 2002;51:597-604.
13. Fialová L, Kalousová M, Soukupová J, Malbohan I, Krofta L, Mikulíková L, et al. Advanced oxidation protein products (AOPP) in the first trimester of pregnancy. Shorn lék 2003;104:95-102.
14. Kalousová M, Fialová L, Zima T, Malbohan IM, Krofta L, Soukupová J, et al. Advanced oxidation protein products in pregnancy. Ces Gynek 2002;67:194-7.
15. Iuliano L, Pratico D, Ferro D, Pittoni V, Valesini G, Lawson J, et al. Enhanced lipid peroxidation in patients positive for antiphospholipid antibodies. Blood 1997;90:3931-5.
16. Lockshin MD. Which patients with antiphospholipid antibody should be treated and how? Rheum Dis Clin North Am 1993;19:235-47.
17. Vaarala O. Antiphospholipid antibodies and myocardial infarction. Lupus 1998;7 Suppl 2:8132-4.
18. Wickens D, Wilkins MH, Lunec J, Ball G, Dormandy TL. Free radical oxidation (peroxidation) products in plasma in normal and abnormal pregnancy. Ann Clin Biochem 1981;18:158-62.
19. Descamps-Latscha B, Witko-Sarsat V. Importance of oxidatively modified proteins in chronic renal failure. Kidney Int 2001;59 Suppl 78:8108-13.
20. Sacks GP, Studena K, Sargent K, Redman CW. Normal pregnancy and preeclampsia both produce inflammatory changes in peripheral blood leukocytes akin to those of sepsis. Am J Obstet Gynecol 1998;179:80-6.
21. Haram K, Augensen K, Elsayed S. Serum protein pattern in normal pregnancy with special reference to acute-phase reactants. Br J Obstet Gynaecol 1983,90:139-45.
22. Nielsen FR, Bek KM, Rasmussen PE, Qvist I, Tobiassen M. C-reactive protein during normal pregnancy. Eur J Obstet Gynecol Reprod Biol 1990;35:23-7.
23. Cuadrado MJ, Khamashta MA. The anti-phospholipid antibody syndrome (Hughes syndrome): therapeutic aspects [review]. Baillieres Best Pract Res Clin Rheumatol 2000;14:151-63.
24. Hörkkö S, Miller E, Dudl E, Reaven P, Curtiss LK, Zvaifler NJ, et al. Antiphospholipid antibodies are directed against epitopes of oxidized phospholipids. Recognition of cardiolipin by monoclonal antibodies to epitopes of oxidized low density lipoprotein. J Clin Invest 1996;98:815-25.
25. Kalousová M, Sulková S, Fialová L, Soukupová J, Malbohan IM, Špaček P, et al. Glycoxidation and inflammation in chronic haemodialysis patients. Nephrol Dial Transplant 2003;18:2577-81.
26. Witko-Sarsat V, Friedlander M, Nguyen-Khoa T, Capeillere-Blandin C, Nguyen At, Canteloup S, et al. Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. J Immunol 1998;161:2524-32.